NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (272)	3/4/1998 7:30:00 PM
From: Miljenko Zuanic	Read Replies (2) of 328

Nexstar reported 4Q/Y results: biz.yahoo.com AmBisome sale in US are not good as expected (~3.3M by Fujisawa) while international sale are almost flat, compared to 3Q. The only positive (financial) are lower manufacturing cost (new plant at San Dimas) and better margin despite price pressure from SEQU/LIPO (this is surprise for me). I am wandering when they will stop eat caviar and drink champagne (R&D and S,G&A expense) because 98 AmBisome revenue will not be sufficient to finance MiKasome and NX1838 development. Without collaboration or significant US penetration with AmBisome (did anyone listen conference call?) thinks may look worse in next few Q. mz

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next